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INTRODUCTION                                                                  
In 1966 Barlow and Bosman(1) described a constellation of clinical 
fi ndings consisting of non-ejection systolic clicks and a late systolic 
murmur, T-wave abnormalities, and systolic aneurysmal billowing of the 
posterior mitral leafl et into the left atrium. Since then, in areas without 
rheumatic heart disease, mitral valve prolapse (MVP) has been 
portrayed as the most common form of valvular heart disease.(2) It is 
characterized by pathological anatomic and physiologic changes in the 
mitral valve apparatus affecting mitral leafl et motion and function. 
ANATOMY OF THE MITRAL VALVE                             
The mitral valve apparatus consists of an annulus, cusps, chordae 
tendineae and papillary muscles. The shape of the mitral valve annulus 
is saddle-like. The mitral valve is functionally bicuspid, but embryologically 
made up of four cusps. Two cusps are large (the anterior or aortic cusp 
and the posterior or mural cusp) and two are small commissural cusps 
(Figure 1). In the case of a normal mitral valve, these commissures are 
never complete.(3) The posterior leafl et is widest around the annulus 
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and divided into three scallops, P1, P2 and P3. The opposing sections 
of the anterior leafl et are designated A1, A2 and A3. The chordae 
tendineae can be divided into three groups. The fi rst two groups 
originate from or near the apices of the papillary muscles. The chordae 
of the fi rst order insert into the extreme edge of the valve. The chordae 
of the second order insert on the ventricular surface of the cusps. The 
chordae of the third order originate from the ventricular wall much 
nearer the origin of the cusps. These chordae often form bands or fold-
like structures that may contain muscle. Usually there are two papillary 
muscles (anterior and posterior), which have bifi d apices; each receive 
chordae from both major mitral valve cusps.
DEFINITION, AETIOLOGY AND PATHOLOGY OF 
MITRAL VALVE PROLAPSE
Normally, the mitral valve billows slightly towards the left atrium; an 
exaggerated form should be termed “billowing mitral valve”. A “fl oppy 
valve” is regarded as an extreme form of billowing. “Prolapse” is defi ned 
as the systolic billowing of one or both mitral valve leafl ets into the 
atrium superior to the annular plane, associated with or without 
regurgitation. A “fl ail valve” involves chordal rupture and is nearly 
always associated with severe mitral regurgitation. 
Many conditions may affect components of the mitral valve apparatus 
and cause secondary prolapse, such as coronary artery disease, 
rheumatic disease, various cardiomyopathies and trauma with elongation 
or rupture of mitral chordae resulting in a fl ail leafl et. More often, a 
primary disorder of the mitral valve leafl ets exists, associated with 
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Mitral valve prolapse (MVP) is the most 
common valvular abnormality, affecting 2.4% of the 
population. Usually MVP is a benign disease and remains 
asymptomatic. The diagnosis of MVP is based on clinical 
presentation, physical examination and echocardiography. 
Some atypical symptoms that are not correlated with 
mitral valve function, are described as the MVP syndrome. 
Potential complications such as infective endocarditis, 
thromboembolic events, atrial and ventricular arrhythmias, 
and progressive mitral valve regurgitation may occur. 
Management should concentrate on adequate guidance 





FIGURE 1: Anatomy of the mitral valve.
The mitral valve is functionally 
bicuspid. The posterior leaﬂ et is 
divided into three scallops: P1, P2 
and P3; the opposing sections of the 
anterior leaﬂ et are designated A1, 
A2 and A3. Embryologically the 
mitral valve consists of four cusps: 
the anterior cusp A1-3, a large 
central posterior cusp P2, and two 
small commissural cusps P1 & P3. 
The commissures in the posterior 
leaﬂ et are not complete.
13059 SAHJ journal October.indd   14 11/8/07   9:33:15 AM
15
Vol. 4, No. 4, 2007
specifi c pathologic changes causing redundancy of the valve leafl ets and 
their prolapse into the left atrium during systole.
Surgeons differentiate into two different forms of degenerative mitral 
valve disease: Barlow’s disease and fi broelastic defi ciency.(4) Barlow’s 
disease is a more generalized form of valve degeneration and has a 
myxoid appearance of the whole valve with excess tissue and a dilated 
annulus, whereas fi broelastic defi ciency has thickening restricted to the 
prolapsed area(s), with the remaining valve tissue being more 
transparent, not thickened, without excess tissue and the annulus being 
dilated or not.(5) 
The exact aetiology of primary MVP is unknown. Individuals with MVP 
are usually of a slender body habitus indicating higher rates of linear 
growth, suggesting that the connective tissue is of lesser quality and 
gives less resistance to linear growth. This is observed in its most 
extreme form in Marfan’s syndrome. MVP might result from a mild 
imbalance of the growth dynamics of the mitral valve apparatus 
especially between the leafl ets, the chordae tendineae and the rest of 
the heart.(6) Such imbalance may be transient with complete 
disappearance of MVP. In many patients an abnormal metabolism of 
collagen associated with an overproduction of mucopolysaccharides 
results in thickening of one or both mitral valve leafl ets and a redundancy 
of the mitral valve leafl et(s) area.(7) Indeed the characteristic microscopic 
feature of primary MVP is a marked proliferation of the spongiosa, the 
myxomatous connective tissue between the atrialis and the fi brosa or 
ventricularis that supports the leafl et. In secondary MVP, no occurrence 
of myxomatous proliferation of the spongiosa is found.(8)
When the leafl ets become grossly abnormal and redundant with 
increasing quantities of myxoid stroma, they may prolapse. In addition, 
regions of endothelial disruption occur and become possible sites of 
thrombus formation or endocarditis. Even the mitral valve annulus and 
the chordae tendineae can be affected by a myxomatous proliferation, 
resulting in chordal rupture and worsening of a pre-existing mitral valve 
regurgitation. Myxomatous changes in the annulus can cause annular 
dilatation and calcifi cation, contributing to the severity of the mitral 
valve regurgitation. 
PREVALENCE OF MITRAL VALVE PROLAPSE                  
Primary MVP is the most frequently diagnosed cardiac valvular 
abnormality, the most frequent cause of signifi cant mitral valve 
regurgitation and the most common substrate for mitral valve 
endocarditis. MVP appears to exhibit a strong hereditary component 
transmitted as an autosomal trait.(9) When using strict criteria and 
adequate diagnostic tools a prevalence of 2.4% without preponderance 
in age or gender is observed.(6) 
Primary MVP occurs mostly as an isolated valve dysfunction, but can 
also be associated with connective tissue diseases such as Marfan’s 
syndrome, Ehlers-Danlos syndrome, osteogenesis imperfecta and 
muscular dystrophy. In addition, MVP seems also to be associated with 
congenital cardiac abnormalities such as Ebstein malformation of the 
tricuspid valve, secundum type atrial septal defect and Holt-Oram 
syndrome. 
EARLY PRESENTATION OF MITRAL VALVE PROLAPSE
Most of the patients with primary MVP remain asymptomatic. The 
diagnosis is often made by a routine cardiac auscultation or by 
echocardiography performed for other reasons. The diagnosis of MVP 
is sometimes considered in patients who have thoracic skeletal 
abnormalities refl ecting suboptimal connective tissue: the most 
common of these are scoliosis, pectus excavatum, straightened thoracic 
spine and narrowed anteroposterior diameter of the chest.
Some patients with primary MVP become symptomatic without 
signifi cant mitral valve dysfunction. Chest discomfort, anxiety, fatigue, 
atypical dyspnea with exercise, at rest and nocturnal, atypical palpitations, 
orthostatism and neuropsychiatric symptoms, which are not correlated 
with mitral valve function, are described as the MVP syndrome 
 FIGURE 2: left ventricular long axis view. The posterior leaﬂ et shows signiﬁ cant 
prolapse.  




(MVPS).(10) The cause of these latter symptoms in the MVP syndrome 
is unknown, but an association between dysfunction of the autonomous 
nervous system and MVP is suggested. 
MVP may be complicated by more serious events such as infective 
endocarditis, thromboembolic events, atrial and ventricular arrhythmia, 
and rarely by syncope and sudden cardiac death. 
On physical examination, MVP is characterized by an apical mid- or late 
systolic click, at least 140 ms after the fi rst heart sound, after the 
beginning of the carotid pulse upstroke; the click can be intermittent 
and may be aggravated by manoeuvres such as squatting or leaning 
forward. It seems to be caused by the sudden systolic tensing of the 
mitral valve apparatus as the leafl ets billow into the left atrium. Any 
manoeuvre that decreases left ventricular volume, such as Valsalva 
manoeuvre, sudden standing, early during inhalation of amyl nitrate, 
tachycardia or augmentation of contractility, results in an earlier 
occurrence of prolapse during systole. In contrast, when left ventricular 
volume is augmented such as during a sudden change from standing to 
supine position, leg-raising, squatting, maximal isometric exercise, 
decreased contractility and expiration, the click will be delayed. The 
sensitivity of a click for diagnosis of MVP is low (19%) but its specifi city 
is high: a mid- or late systolic click can be heard in the absence of MVP 
in only 1.5% of cases.
MVP is often associated with mitral valve regurgitation. Therefore, in 
one-third of the patients, the midsystolic click is followed by a typical 
apical late systolic heart murmur.(11) 
The electrocardiogram is often normal in patients with MVP. The most 
common abnormality is the presence of ST-T wave depression or T-
wave inversion in the inferior leads.(12) Exercise testing is frequently 
false-positive with ST-T wave depression, especially in women, even 
with normal coronary arteries.(13)
The two-dimensional transthoracic or transoesophageal echo-
cardiography is the easiest diagnostic tool to confi rm the diagnosis of 
MVP.(14) Two-dimensional views display the leafl ets and the annulus of 
the mitral valve, but the images must be interpreted in the context of 
the three-dimensional saddle-like shape of the valve. The nonplanar 
“saddle shape” of the normal mitral leafl ets can give the appearance of 
prolapse in certain echocardiographic views. The echocardiographic 
criteria used for the diagnosis of a classic MVP are a dislocation > 2 mm 
to the left atrium of at least one of the mitral valve leafl ets during 
systole and a thickening ≥ 5 mm of the prolapsing valve leafl et during 
diastole. Dislocation is referred by a hypothetical line through the 
insertion points of the anterior and the posterior mitral valve leafl et in 
parasternal and apical long axis view.
The newest generation of two- and three-dimensional transthoracic 
and transoesophageal echocardiography machines generates exquisite 
images, allowing one to clearly identify the mechanism of mitral 
regurgitation and to differentiate Barlow’s disease from fi broelastic 
defi ciency.(15) In patients who require a surgical intervention, the 
possibilities of reconstructive surgery can be better assessed, ensuring 
optimal treatment by use of the best technique. Recently, the use of 
stress or exercise echocardiography has been advocated.(16) 
The most typical MVP is characterised by important mitral valve 
regurgitation, signifi cant enlargement of the mitral valve leafl ets and 
annulus, elongation of the chordal apparatus and loss of leafl et 
apposition. At the other end of the spectrum, patients with mild bowing 
and normal-appearing leafl ets should be considered as normal variants 
because their risk of adverse events probably does not differ from that 
in the general population. 
EARLY MANAGEMENT OF MITRAL VALVE PROLAPSE 
Most patients with MVP require no treatment. Management of MVP 
(Table 1) should be centered on patient education, symptom 
recognition and risk management. For those patients with MVP without 
leafl et thickening and regurgitation, patient education is the only 
treatment indicated. It should focus on the generally benign nature of 
the condition and reassure patients that they can live long and healthy 
normal lives. Oral antibiotic prophylaxis is not required. Follow-up 
echocardiography in 5 years is reasonable, unless other symptoms 
warrant evaluation sooner.
Patients with mild regurgitation and/or valve abnormalities require 
preventive oral antibiotic prophylaxis. Infective endocarditis is a serious 
complication of MVP and MVP with regurgitation is considered as the 
leading predisposing cardiovascular disorder in patients with endocarditis. 
Although a low incidence of surgical need (7.5%) and lethal outcome 
(5%), frequent (25%) neurological complications were found associated 
with infective endocarditis. Even mild hypertension should be treated, 
as this may aggravate mitral valve dysfunction. Similarly, weight control 
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should be encouraged. Echocardiographic reevaluation at 2- to 3-year 
intervals is appropriate.
At highest risk are those who suffer from a moderate-to-severe mitral 
regurgitation. This group is most likely to require valve surgery, and 
every effort should be made to reduce factors that increase regurgitation. 
High-risk patients require yearly Doppler evaluation. Valve surgery 
should be considered in patients who have worsening dyspnea and 
diminishing left ventricular function.
When the presence of arrhythmias is suspected, 24 hours’ ECG 
recording needs to be performed to determine an antiarrhythmic 
strategy.
In patients who have symptoms suggestive of MVPS, lifestyle 
modifi cation is the key to reducing symptoms. Dietary changes such as 
avoidance of caffeine may reduce palpitations. In addition, these patients 
often seem to respond to therapy with beta blockers.(17) Orthostatic 
symptoms related to postural hypotension and tachycardia are best 
treated with volume expansion, increasing fl uid and salt intake.
LATE OUTCOME OF MITRAL VALVE PROLAPSE          
When patients with MVP become symptomatic, the symptoms are 
mostly associated with the complications that cause the dysfunction of 
the mitral valve. MVP has a complication rate of less than 2% per year, 
most likely in those patients with a murmur, left atrial or left ventricular 
enlargement.(18) 
MVP patients with leafl et thickening and redundancy seem to be at 
highest risk for developing valve regurgitation. The risk of progression 
of mitral valve regurgitation also increases with age, male sex, elevated 
blood pressure and high body weight (both of which may explain the 
male majority). 
Leafl et thickening and redundancy put patients at risk for infectious 
bacterial endocarditis. The risk of developing endocarditis is low 
(1-3.5%), but oral antibiotic prophylaxis remains important.
The incidence of stroke in MVP patients is higher than in the general 
population. The reason is not clearly understood, and currently there 
are no clinical clues to predict the risk of stroke. Those with severe 
mitral valve regurgitation seem to be at greater risk, regardless of 
whether their regurgitation is a result of prolapse. Loss of endothelial 
continuity and tearing of the endocardium overlying the myxomatous 
valve may initiate platelet aggregation. Patients without symptoms of 
transient ischemic attacks do not need anti-platelet treatment. 
Repetitive atrial arrhythmias and complex ventricular arrhythmias are 
more common in MVP. 
Supraventricular arrhythmias are found to be less frequent than 
ventricular arrhythmias. Premature supraventricular contractions are 
observed in 35% of those with MVP but also in a similar number of 
normal individuals. Sinus tachycardia (heart rate greater than 120 beats 
per minute), paroxysmal atrial tachycardia and intermittent atrial 
fi brillation are not more common than in control subjects. Nevertheless, 
atrial fi brillation is seen more frequently in mitral valve prolapse when 
TABLE 1: Management of patients with mitral valve prolapse.
Asymptomatic patients 
Absence of mitral valve regurgitation
 Follow-up frequency: every 5 years
 Technical examinations
  Electrocardiogram
  Two-dimensional echocardiography and Doppler
 No endocarditis prophylaxis required
 Competitive exercise allowed
Presence of stable mild mitral valve regurgitation
 Follow-up frequency: every 2-3 years 
 Technical examinations
  Electrocardiogram
  Two-dimensional echocardiography and Doppler
 Endocarditis prophylaxis required
  Moderate static and moderate dynamic competitive sports allowed            
Presence of progressive mitral valve regurgitation
 Follow-up frequency: at least every year
 Technical examinations
  Electrocardiogram
  Two-dimensional echocardiography and Doppler
  Chest X-ray
 Endocarditis prophylaxis required
 Recreational sport allowed
Symptomatic patients
Not attributable to moderate/severe mitral valve regurgitation 
 Follow-up frequency: every year
  Technical examinations
  Electrocardiogram
  24-hour electrocardiographic monitoring
  Treadmill exercise testing
 If necessary: anti-arrhythmic drugs (bèta-adrenoreceptor blocker)
Attributable to moderate/severe mitral valve regurgitation
 Technical examinations 
  Invasive hemodynamic evaluation
  Transoesophageal echocardiogram, 3D 
 Mitral valve surgery
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mitral regurgitation is present. Complex premature ventricular 
complexes correlate with QT dispersion in patients with MVP. 
Therefore, QT dispersion might be a useful marker of cardiovascular 
morbidity and mortality due to complex ventricular arrhythmias. A 
correlation between QT interval and ventricular arrhythmias in patients 
with MVP has been suggested but remains unconfi rmed.(19) 
The risk of syncope or sudden death is 0.1% per year, hardly any 
different to that of the rest of the general adult population (0.2%). 
However, this risk may attain 0.9-2% in patients with mitral valve 
regurgitation. In addition, between 3% and 5% of cardiac-related sudden 
deaths during exercise are attributed to MVP. The causes of sudden 
death related with MVP are unclear (hemodynamic, neurohumoral, 
arrhythmic, etc.), although there is evidence in favor of malignant 
ventricular arrhythmias.(20) Detailed studies have raised doubts as to the 
direct involvement of the cardiovascular malformation in this mode of 
fatal outcome. In cases of sudden death linked to MVP, localized or 
diffuse myocardial disease is often observed in association with MVP 
(usually asymptomatic or pauci-symptomatic) providing a more 
plausible cause for sudden death.
LATE MANAGEMENT OPTIONS                                                        
When MVP results in signifi cant mitral valve regurgitation, valve surgery 
is necessary. No clinical data are available proving benefi t of long-term 
vasodilator therapy in symptomatic or non-symptomatic patients with 
MVP, although salutary hemodynamic effects were noticed during 
short-term administration of pre- and afterload reduction. 
Initially, mitral valve replacement by a mechanical or, less often, biological 
valve was performed. Currently most patients will be offered 
reconstructive surgery.(21) Several techniques can be applied: intervention 
at the leafl et (quadrangular resection, triangular resection, plication, 
cleft closure), intervention at the annulus (sliding plasty, plication, 
decalcifi cation), at the chordae (shortening, transposition, artifi cial 
chordae), shortening of the papillary muscles, and the placement of an 
annuloplasty ring. Techniques through a small thoracotomy or 
thoracoscopic approach with robotic assistance or transapical approach 
have been developed for well selected patients.(22) Mitral valve repair 
currently has low operative mortality (< 1-2%) and is associated with 
MITRAL 
VALVE PROLAPSE
excellent early short-term results, most patients leaving the hospital 
with residual regurgitation of less than ¼.(23) Follow-up studies suggest 
a lower risk of thrombosis and endocarditis with valve repair rather 
than valve replacement.
However, myxomatous valve leafl ets are structurally, biochemically, 
physically and mechanically abnormal and a certain progression of the 
disease can be expected post-repair. When avoiding subideal techniques 
(chordal shortening instead of transposition or artifi cial chordae, 
the non-use of an annuloplasty ring, and the non-use of a sliding 
plasty) the recurrence rate of signifi cant mitral regurgitation 
(colour Doppler grade >2/4) is 2.9% in Barlow’s disease and 2.2% in 
fi broelastic defi ciency, which seems related to progression of 
valve degeneration. (12, 24) Freedom from reoperation for fi broelastic 
defi ciency is better (96.6% at 10 years) than for Barlow’s disease (86.1% 
at 10 years). 
PREGNANCY                                                                                     
Primary MVP is considered to be the most common valvular heart 
lesion in adult females of reproductive age. In general, pregnancy and 
labor are well tolerated in patients with hemodynamically stable MVP. 
Supraventricular and ventricular arrhythmias are considered to be one 
of the most frequent complications during pregnancy in females with 
MVP and often require treatment with antiarrhythmic drugs. The 
incidence of preterm delivery is not increased in patients with MVP. 
Infective endocarditis prophylaxis is recommended as indicated. 
EXERCISE AND MITRAL VALVE PROLAPSE                         
Aerobic exercise should be encouraged for all patients with MVP. An 
aerobic exercise program seems to improve the symptoms and 
functional capacity of patients with documented MVP. Patients with 
MVP often have low resting blood pressure, thought to be related to 
low intravascular volume. This is of particular importance to athletes 
with MVP because they may be more sensitive to dehydration induced 
by vigorous physical activity, and thus at higher risk for exercise-induced 
syncope.
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Current recommendations are as follows:(25)
Athletes with MVP (having a structurally abnormal valve manifested by 
leafl et thickening and elongation) and without any of the following 
criteria can engage in all competitive sports: 
History of syncope, documented to be arrhythmogenic in origin; 
Family history of sudden death associated with MVP; 
 Repetitive forms of sustained and nonsustained supraventricular 
arrhythmias, particularly if exaggerated by exercise; 
Moderate-to-marked mitral regurgitation; 
Prior embolic event. 
Athletes with MVP and one or more of the aforementioned criteria can 
participate in only low-intensity competitive sports.
Exercise recommendations vary for patients who have MVP with mild 






size and function can participate in all competitive sports. Athletes in 
sinus rhythm or atrial fi brillation with mild left ventricular enlargement 
and normal left ventricular function at rest can participate in low and 
moderate static and moderate dynamic competitive sports. 
Athletes with defi nite left ventricular enlargement or any degree of left 
ventricular dysfunction at rest should not participate in any competitive 
sports. Patients on chronic anticoagulation therapy should avoid sports 
involving body contact.
CONCLUSIONS                                                                    
MVP has caused confusion and concern on the part of both patients 
and physicians. Over the past two decades, more has been learnt about 
the epidemiology, pathophysiology, diagnosis and treatment of this 
condition, allowing a rational approach to the management and 
treatment of patients with MVP. It is important to differentiate between 
the normal variant forms and the primary form of MVP. 
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